SynZeal FAQ's

Canagliflozin

Jan 13, 2021

Canagliflozin is the anhydrous form of canagliflozin, a C-glucoside with a thiophene ring that is an orally available inhibitor of sodium-glucose transporter 2 (SGLT2) with antihyperglycemic activity. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type2diabetesmellitus.

product

Cabazitaxel

Jan 11, 2021

Cabazitaxel is a semi-synthetic derivative of the natural Taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel is used to treat people with prostatecancer that has progressed despite treatment with docetaxel. It was approved by Food and Drug Administration (FDA) in 2010.

product

Bortezomib

Jan 02, 2021

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The boron atom in bortezomib binds the catalytic site of the 26S proteasome with high affinity and specificity. In May 2003, bortezomib became the first anticancerproteasome inhibitor that was approved by the FDA.

product

Bupropion

Nov 10, 2020

Bupropion is an aminoketone with antidepressant activity. Bupropion is a unicyclic aminoketone that belongs to the class of substituted cathinones and the more general class of substituted phenethylamines. Bupropion is a medication primarily used to treat major depressivedisorder and to support smokingcessation. It was approved by the USFDA as an antidepressant.

product

Budesonide

Nov 09, 2020

Budesonide is used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide belongs to the class of organiccompounds known as 21-hydroxysteroids. During the 2020 COVID-19 pandemic, researchers observed that patients already prescribed inhaled corticosteroids appeared to develop less serious illness when diagnosed with covid19

product

Brivaracetam

Nov 01, 2020

Brivaracetam is an orally bioavailable levetiracetam derivative, with anticonvulsant activity. Brivaracetam is used in the treatment of partial-onset seizures. Brivaracetam was approval on February 19, 2016.

product

Brexpiprazole

Oct 30, 2020

Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is an atypical antipsychotic used in the treatment of schizophrenia and major depressivedisorders. In January 2018, it was approved .

product

Bosutinib

Oct 29, 2020

Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Bosutinib was approved on September 4, 2012.

product

Ampicillin

Oct 28, 2020

Ampicillin is a broad-spectrum, semi-synthetic, beta-lactam penicillin antibiotic with bactericidalactivity. Ampicillin is an antibiotic used to prevent and treat a number of bacterialinfections, such as infections, urinary, meningitis, salmonellosis, and endocarditis. Ampicillin was discovered in 1958 and came into commercial use in 1961.

First
3
4
5
6
7

BLOGS

Canagliflozin

Cabazitaxel

Bortezomib

Bupropion

Budesonide

Brivaracetam

Brexpiprazole

Bosutinib

Ampicillin